A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
Incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play a major role in regulation of postprandial glucose and the development of type 2 diabetes mellitus. The incretins are rapidly metabolized, primarily by the enzyme dipeptidyl‐peptidase 4 (DPP...
Saved in:
Main Authors: | Pavel Balazki (Author), Stephan Schaller (Author), Thomas Eissing (Author), Thorsten Lehr (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE−/− mice by blocking monocyte/macrophage activation
by: Florian Kahles, et al.
Published: (2018) -
Non Incretin Effects of DPP-4 Inhibitors: Comparative Study
by: A Shabbir Ali Bhatti, et al.
Published: (2019) -
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024) -
INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024) -
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
by: Sigrid Jall, et al.
Published: (2017)